Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation.
Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approachIpsen to pay Marengo $45 million upfront with potential for additional milestone paymentsPARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News:Ipsen (.
- Alain Baron, M.D., Escient Co-founder and CEO Retires -SAN DIEGO (BUSINESS WIRE) Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass, MBA as Chief Execut.